Why Analysts Are Rethinking Roivant Sciences After Strong Phase 3 Results and Analyst Upgrades [Yahoo! Finance]
Roivant Sciences Ltd. (ROIV)
Company Research
Source: Yahoo! Finance
rising from $18.30 to $20.05 after the release of strong Phase 3 dermatomyositis data. This upward revision highlights growing optimism around the company's recent clinical milestones and strategic progress. Stay tuned to discover how to monitor further updates and evolving perspectives on Roivant Sciences in the months ahead. What Wall Street Has Been Saying Analyst commentary following Roivant Sciences' recent clinical updates reflects a broadly constructive outlook, with a notable tilt toward optimism. However, some caution remains among select market observers. The following summarizes key takeaways from recent analyst research and commentary. ?? Bullish Takeaways Analysts at JP Morgan and Piper Sandler have raised their price targets substantially, with Piper Sandler increasing its target to $23 following the announcement of robust Phase 3 dermatomyositis data for brepocitinib. Bullish research highlights improving commercial execution prospects and effective cost contr
Show less
Read more
Impact Snapshot
Event Time:
ROIV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ROIV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ROIV alerts
High impacting Roivant Sciences Ltd. news events
Weekly update
A roundup of the hottest topics
ROIV
News
- Vivek Ramaswamy's Net Worth Has Nearly Doubled While He's Running For Ohio Governor [Forbes]Forbes
- Roivant Sciences (NASDAQ:ROIV) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=ROIV&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street ZMarketBeat
- Roivant Sciences (NASDAQ:ROIV) had its "buy" rating reaffirmed by analysts at Guggenheim.MarketBeat
- Roivant Sciences: Brepocitinib And Roadmap Still Underpriced [Seeking Alpha]Seeking Alpha
- Roivant Sciences (NASDAQ:ROIV) had its price target raised by analysts at Citigroup Inc. from $25.00 to $26.00. They now have a "buy" rating on the stock.MarketBeat
ROIV
Earnings
- 11/10/25 - Beat
ROIV
Sec Filings
- 11/24/25 - Form 4
- 11/24/25 - Form 4
- 11/21/25 - Form 4
- ROIV's page on the SEC website